Norway Expansion And EU Approvals Will Strengthen Future Position

Key Takeaways

• Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.
  
• Retaining full rights to MOB-015 improves margins and control over commercialization, with supply chain enhancements ensuring stable product availability.
  
• Delays in U.S. launch, cautious European expansion, and terminated partnerships threaten Moberg Pharma's short-term revenue growth and international market penetration.

Catalysts

A pharmaceutical company, develops and commercializes medical products primarily in Sweden.

• The expansion into Norway represents a key milestone within Moberg Pharma's European growth strategy, expected to drive revenue increases through market share capture and increased reach in new European markets.
  
• Obtaining 13 EU market approvals positions the company well for a broader European rollout, enhancing future revenue potential and setting the groundwork for significant sales growth anticipated in 2026.
  
• Strategic decisions to retain full rights to MOB-015 in Europe, following the end of partnerships, are expected to improve net margins and strengthen control over commercialization efforts, thereby enhancing brand positioning.
  
• Securing a new terbinafine supply chain eliminates previous bottlenecks, supporting revenue growth by enabling reliable product availability for expansion efforts and ensuring long-term operational success.
  
• Planned additional U.S. clinical studies for FDA approval, while capital intensive initially, are likely to drive long-term earnings growth by expanding market opportunities and enhancing global marketing claims once successfully executed.

Moberg Pharma Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Moberg Pharma's revenue will grow by 95.3% annually over the next 3 years.
• Analysts assume that profit margins will increase from -129.0% today to 29.8% in 3 years time.
• Analysts expect earnings to reach SEK 37.2 million (and earnings per share of SEK 0.6) by about August 2029, up from -SEK 21.6 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.4x on those 2029 earnings, up from -24.1x today. This future PE is lower than the current PE for the GB Pharmaceuticals industry at 49.2x.
• Analysts expect the number of shares outstanding to decline by 0.27% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.45%, as per the Simply Wall St company report.

Risks

• The Phase III study for MOB-015 in North America did not meet its primary endpoint, necessitating additional clinical studies for FDA approval, which delays the U.S. launch and impacts potential revenue from the U.S. market.
  
• The company's decision to recognize an intangible asset impairment indicates financial prudence but also highlights risk, potentially affecting net margins due to the extended timeline and additional costs associated with further studies.
  
• Moberg Pharma's market expansion is cautious, as it is significantly focused on Europe, with many European market rollouts not expected until 2026, thereby delaying potential revenue growth and impacting near-term financial performance.
  
• The termination of market partnerships in South Korea and with Bayer poses a risk to international market penetration, potentially affecting expected earnings from these regions due to challenging market conditions and strategic resource reallocation.
  
• The necessity to secure terbinafine supply and complete internal regulatory steps before expanding to more EU markets could delay entry into potentially profitable markets, impacting future revenue opportunities.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of SEK16.0 for Moberg Pharma based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK124.9 million, earnings will come to SEK37.2 million, and it would be trading on a PE ratio of 23.4x, assuming you use a discount rate of 5.5%.
• Given the current share price of SEK11.08, the analyst price target of SEK16.0 is 30.8% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.